Ezetimiba (Ezetimibe) API Manufacturers & Suppliers

Ezetimibe (CAS 163222-33-1) is an intestinal cholesterol absorption inhibitor used to manage primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. It is administered as adjunct therapy to dietary modification and may be used alone or in combination with statins or fenofibrate depending on the clinical context.

Its pharmacological effect is based on selective inhibition of the Niemann-Pick C1-Like 1 transporter, a critical mediator of sterol uptake at the apical surface of enterocytes and at the hepatobiliary interface. By blocking formation or internalization of the NPC1L1–sterol complex, ezetimibe reduces the entry of cholesterol and phytosterols into enterocytes, leading to decreased hepatic cholesterol stores and increased clearance of circulating cholesterol. This mechanism does not interfere with the absorption of fat-soluble vitamins, triglycerides, or bile acids.

Clinically, ezetimibe reduces total cholesterol, LDL cholesterol, apolipoprotein B, non-HDL cholesterol, and triglycerides while providing modest increases in HDL cholesterol. Greater lipid-lowering effects occur when combined with statins or fenofibrate. In familial hypercholesterolemia and sitosterolemia, typical LDL reductions range from approximately 15 to 20 percent with small increases in HDL cholesterol.

Following oral administration, ezetimibe undergoes intestinal and hepatic glucuronidation and circulates mainly as its active glucuronide. Enterohepatic recycling contributes to its duration of action. It is a substrate for UGT1A1, UGT1A3, and UGT2B7, and interacts with several transporter systems including OATP1B1, BCRP, BSEP, and P-glycoprotein.

Safety considerations include avoidance in moderate to severe hepatic impairment due to limited clinical data, and vigilance for myopathy or rhabdomyolysis, particularly when co-administered with statins. Post-marketing experience suggests that these muscle-related effects remain uncommon but clinically relevant.

In procurement, sourcing teams should prioritize material with robust impurity control, validated stereochemical integrity, and compliance with pharmacopeial and regional regulatory standards to support reliable formulation performance and global registration.